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BACKGROUND
World Health Organization expert groups recommended mortality trials of four 
repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and inter-
feron beta-1a — in patients hospitalized with coronavirus disease 2019 (Covid-19).
METHODS
We randomly assigned inpatients with Covid-19 equally between one of the trial 
drug regimens that was locally available and open control (up to five options, four 
active and the local standard of care). The intention-to-treat primary analyses ex-
amined in-hospital mortality in the four pairwise comparisons of each trial drug 
and its control (drug available but patient assigned to the same care without that 
drug). Rate ratios for death were calculated with stratification according to age 
and status regarding mechanical ventilation at trial entry.
RESULTS
At 405 hospitals in 30 countries, 11,330 adults underwent randomization; 2750 
were assigned to receive remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir 
(without interferon), 2063 to interferon (including 651 to interferon plus lopinavir), 
and 4088 to no trial drug. Adherence was 94 to 96% midway through treatment, 
with 2 to 6% crossover. In total, 1253 deaths were reported (median day of death, 
day 8; interquartile range, 4 to 14). The Kaplan–Meier 28-day mortality was 11.8% 
(39.0% if the patient was already receiving ventilation at randomization and 9.5% 
otherwise). Death occurred in 301 of 2743 patients receiving remdesivir and in 303 
of 2708 receiving its control (rate ratio, 0.95; 95% confidence interval [CI], 0.81 to 
1.11; P = 0.50), in 104 of 947 patients receiving hydroxychloroquine and in 84 of 
906 receiving its control (rate ratio, 1.19; 95% CI, 0.89 to 1.59; P = 0.23), in 148 of 
1399 patients receiving lopinavir and in 146 of 1372 receiving its control (rate ratio, 
1.00; 95% CI, 0.79 to 1.25; P = 0.97), and in 243 of 2050 patients receiving inter-
feron and in 216 of 2050 receiving its control (rate ratio, 1.16; 95% CI, 0.96 to 1.39; 
P = 0.11). No drug definitely reduced mortality, overall or in any subgroup, or re-
duced initiation of ventilation or hospitalization duration.
CONCLUSIONS
These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little 
or no effect on hospitalized patients with Covid-19, as indicated by overall mortal-
ity, initiation of ventilation, and duration of hospital stay. (Funded by the World 
Health Organization; ISRCTN Registry number, ISRCTN83971151; ClinicalTrials.gov 
number, NCT04315948.)
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In February 2020, a World Health Orga-nization (WHO) research forum on corona-virus disease 2019 (Covid-19) recommended 
evaluation of treatments in large, randomized 
trials,1 and other WHO expert groups identified 
four repurposed antiviral drugs that might have 
at least a moderate effect on mortality: remdesivir, 
hydroxychloroquine, lopinavir, and interferon 
beta-1a.2 In March 2020, the WHO began a large, 
simple, international, open-label, randomized trial 
involving hospital inpatients to evaluate the ef-
fects of these four drugs on in-hospital mortality. 
The trial was adaptive; unpromising drugs could 
be dropped and others added. Hydroxychloro-
quine, lopinavir, and interferon were eventually 
dropped from the trial, but others, such as mono-
clonal antibodies, will be added. We report interim 
results for the original four drugs.
Me thods
Trial Design
The protocol, which was published previously3 and 
is available with the full text of this article at 
NEJM.org, was designed to involve hundreds of 
hospitals in dozens of countries. Trial procedures 
were minimal but rigorous, with data entry through 
a cloud-based Good Clinical Practice–compliant 
clinical data management system that recorded 
demographic characteristics, respiratory support, 
coexisting illnesses, and local availability of trial 
drugs before generating the treatment assign-
ment. Written informed consent was provided by 
patients, or if they were unable to do so, by their 
legal representatives.3 Consent forms were retained 
by signatories and encrypted for records. The en-
rollment of patients who provided consent took 
just a few minutes. Eligible patients were 18 years 
of age or older, were hospitalized with a diagnosis 
of Covid-19, were not known to have received 
any trial drug, were not expected to be transferred 
elsewhere within 72 hours, and, in the physician’s 
view, had no contraindication to any trial drug.
The same cloud-based system was used to 
report any suspected unexpected serious adverse 
reaction. It was also used to record death in the 
hospital or discharge alive (with documentation 
of respiratory support in the hospital, trial-drug 
timing, use of nontrial drugs, and probable cause 
of death). National and global monitors raised or 
resolved queries (or both) and checked progress 
and completeness.
Treatment Regimens
The trial drugs were remdesivir, hydroxychloro-
quine, lopinavir, and interferon beta-1a (given with 
lopinavir until July 4). The hydroxychloroquine, 
lopinavir, and interferon regimens were discon-
tinued for futility on, respectively, June 19, July 4, 
and October 16, 2020. Participants were ran-
domly assigned in equal proportions to receive no 
trial drug or one of the trial drug regimens that 
was locally available (up to five options; all pa-
tients were to receive the local standard of care). 
In this open-label trial, no placebos were used.
The controls for a drug were patients assigned 
to the standard of care at a time and place in 
which that drug was locally available (except that 
when interferon was being given only with lopi-
navir, its controls were patients given only lopi-
navir). Assignment to the standard of care at a 
hospital in which more than one trial drug was 
available would put that patient into the control 
group for each of those drugs. Hence, there was 
partial overlap among the four control groups. 
Each comparison between a trial drug and its 
control, however, was evenly randomized (in a 1:1 
ratio) and unbiased, because both groups were 
affected equally by differences between countries 
or hospitals and by time trends in patient char-
acteristics or the standard of care.
Daily doses were those already used for other 
diseases, but to maximize any efficacy without 
undue cardiac risk, the hydroxychloroquine dose 
was based on that for amoebic liver abscess 
rather than the lower dose for malaria.4 (Hydroxy-
chloroquine slightly prolongs the QT interval, 
and an unduly high dose or rapid administration 
might cause arrhythmias or hypotension.) Treat-
ments stopped at discharge.
The regimen for remdesivir (intravenous) was 
200 mg on day 0 and 100 mg on days 1 through 
9. The regimen for hydroxychloroquine (oral) 
was four tablets at hour 0, four tablets at hour 6, 
and, starting at hour 12, two tablets twice daily 
for 10 days. Each tablet contained 200 mg of 
hydroxychloroquine sulfate (155 mg of hydroxy-
chloroquine base per tablet; a little-used alterna-
tive involved 155 mg of chloroquine base per 
tablet). The regimen for lopinavir (oral) was two 
tablets twice daily for 14 days. Each tablet con-
tained 200 mg of lopinavir (plus 50 mg of rito-
navir, to slow hepatic lopinavir clearance). Other 
formulations were not provided, so patients who 
were receiving mechanical ventilation received 
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no trial lopinavir while they were unable to swal-
low. The regimen for interferon (mainly subcuta-
neous) was three doses over a period of 6 days 
(the day of randomization and days 3 and 6) of 
44 μg of subcutaneous interferon beta-1a; where 
intravenous interferon was available, patients 
receiving high-flow oxygen, ventilation, or extra-
corporeal membrane oxygenation (ECMO) were 
instead to be given 10 μg intravenously daily for 
6 days.
Outcomes
The protocol-specified primary objective was to 
assess effects on in-hospital mortality (i.e., death 
during the original hospitalization; follow-up 
ceased at discharge), regardless of whether death 
occurred before or after day 28. The only proto-
col-specified secondary outcomes were the initia-
tion of mechanical ventilation and hospitaliza-
tion duration. Although no placebos were used, 
appropriate analyses of these secondary outcomes 
can still be informative. Add-on studies that were 
led from Canada, France, India, and Norway re-
corded other outcomes (not reported here).
Oversight and Funding
The trial was registered at the ISRCTN Registry 
and ClinicalTrials.gov, with the core protocol 
approved by the WHO ethics review committee 
and local protocols approved by national ethics 
committees and regulatory authorities. Trial con-
duct was in accordance with the principles of the 
Declaration of Helsinki and Good Clinical Prac-
tice guidelines. The only exclusions from the 
intention-to-treat analyses were the few patients 
with no, or uncertain, consent to follow-up. All 
other randomly assigned patients were included. 
The WHO was the global cosponsor and govern-
ments the national cosponsors, with trial gover-
nance by the executive group of the international 
steering committee. External statistical analyses 
for the independent data and safety monitoring 
committee were unseen by the executive group 
or the WHO, with two exceptions. After outside 
evidence of the futility of hydroxychloroquine 
and lopinavir became available, the executive group 
requested unblinded analyses of the findings just 
for these two drugs. In addition, after deciding in 
a blinded fashion to report all interim results, 
the executive group revised this manuscript, which 
has been drafted only by the WHO trial team and 
external statisticians. Remdesivir was donated by 
Gilead Sciences, hydroxychloroquine by Mylan, 
lopinavir by AbbVie, Cipla, and Mylan, and inter-
feron beta-1a by Merck (subcutaneous) and Faron 
Pharmaceuticals (intravenous).
Sample Size
The protocol stated, “The larger the number 
entered the more accurate the results will be, but 
numbers entered will depend on how the epidemic 
develops. . . . it may be possible to enter several 
thousand hospitalised patients with relatively mild 
disease and a few thousand with severe disease, 
but realistic, appropriate sample sizes could not 
be estimated at the start of the trial.” The execu-
tive group, whose members were unaware of the 
findings, made the decision to release the interim 
results.
Statistical Analysis
The intention-to-treat analyses related outcome 
to assigned treatment. The primary analyses were 
of in-hospital mortality among all randomly as-
signed patients (each drug vs. its control). The 
only protocol-specified subgroup analyses involved 
patients who already had severe disease at entry 
and those who did not. Severity was not protocol-
defined, but separate analyses are provided regard-
ing those receiving some supplemental oxygen or 
none and for those already receiving ventilation 
at entry or not. Rate ratios for death (or, equiva-
lently, hazard ratios) and P values are from log-
rank analyses stratified according to six strata of 
age and ventilation status at entry. Graphs of 
mortality according to time are from unstratified 
Kaplan–Meier methods, with denominators cho-
sen to yield in-hospital mortality. (For example, 
if 99 of 100 patients were discharged alive before 
the last one died, the in-hospital mortality would 
be 1% and at the time of that death the probabil-
ity of not having died in the hospital was multi-
plied by 99/100; this denominator included those 
already discharged.)
The risk on day N was calculated by first ex-
cluding patients with an outcome not reported or 
an entry fewer than N days before data-set closure 
(or transferred elsewhere before day N); then, the 
number of in-hospital deaths on day N was di-
vided by the total number of patients in the hos-
pital on day N or discharged alive before day N. 
This denominator (or “risk set”), which includes 
those discharged before day N, was also used to 
calculate the contribution of day N to log-rank 
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analysis and Cox analysis of in-hospital mortal-
ity. Denominators for the few deaths on day 0, 
but not on later days, included patients with no 
follow-up reported (because if any patient died 
on the day of randomization, this would proba-
bly have been reported).
If the stratified log-rank observed minus ex-
pected number of deaths is O − E with variance V, 
the loge rate ratio is calculated as (O − E)/V with 
variance 1/V and a normal distribution. If event 
times are accurate and b is the log hazard ratio 
and L(b) the Cox log-likelihood, the first and 
second derivatives of L(b) at b = 0 are (O − E) and 
–V.5 Forest plots (with 95% confidence intervals 
only for overall trial results; otherwise, with 
99% confidence intervals to allow for subgroup 
multiplicity) and chi-square statistics (sum of 
[O − E]2/V, without any P value) help interpret any 
heterogeneity of rate ratios between subgroups. 
All rate ratios describe proportional risk reduc-
tions; absolute risk reductions would also depend 
on background risks. Analyses were performed 
with the use of SAS software, version 9.4, and 
R software, version 4.02.
Meta-analyses of the major trial results are 
based on the inverse-variance–weighted average 
of b = loge rate ratio from each stratum of each 
trial, with the use of odds ratios when hazard 
ratios or rate ratios for death were unavailable. 
(This weighted average is derived from the sums 
of [O − E] and of V over strata.5) In general, the 
more deaths in a stratum the larger V is and, 
correspondingly, the smaller is the variance of the 
loge rate ratio, so the more weight that stratum 
gets. The variance that is attributed to the result 
in each stratum and to the overall weighted aver-
age reflects only the play of chance at random-
ization. Homogeneity of different rate ratios is 
not needed for such a weighted average to be 
informative.
R esult s
Patient Characteristics and Adherence
From March 22 to October 4, 2020, a total of 
11,330 patients were entered in the trial from 
405 hospitals in 30 countries in all six WHO 
regions. Of these patients, 64 (0.6%) had no, or 
uncertain, consent to follow-up, which left 11,266 
in the intention-to-treat analyses. A total of 2750 
patients were assigned to receive remdesivir, 954 
to hydroxychloroquine, 1411 to lopinavir (without 
interferon), 2063 to interferon (including 651 to 
interferon plus lopinavir), and 4088 to no trial 
drug (Fig. 1); reporting is 97% complete for those 
who were entered more than 1 month earlier 
and 99.7% complete for those who were entered 
more than 3 months earlier. All 3 patients for 
whom the diagnosis of Covid-19 was later ruled 
out were included in the analyses and survived. 
Table 1 shows patient characteristics: 9120 (81%) 
were younger than 70 years of age, 6985 (62%) 
were male, 2768 (25%) had diabetes, 916 (8%) were 
already receiving ventilation, and 7002 (62%) un-
derwent randomization on days 0 or 1. For each 
drug, patient characteristics were well balanced 
by the unstratified 1:1 randomization between it 
and its control. Deaths were at a median of day 8 
(interquartile range, 4 to 14), and discharges were 
at a median of day 8 (interquartile range, 5 to 12).
There were 1253 in-hospital deaths (the pri-
mary outcome, including those before and after 
day 28). The Kaplan–Meier risk of in-hospital death 
to day 28 was 11.8%; a few in-hospital deaths 
occurred later. This risk depended on several 
factors, particularly age (20.4% if ≥70 years and 
6.2% if <50 years) and ventilation status (39.0% if 
the patient was already receiving ventilation and 
9.5% otherwise).
Table 1 also shows adherence. For remdesivir, 
the scheduled treatment duration was 10 days (or 
to death or discharge). Of those assigned to rem-
desivir, 98% began treatment. Midway through 
this period, 96% of the patients were still taking 
it (as compared with only 2% of those in the rel-
evant group). Similarly, for other drugs adherence 
midway was 94% to 95%, and crossover was 2 to 
6%. Trial treatments ceased on schedule (if the 
patient was still in the hospital). Absolute differ-
ences (active vs. control) in the use of glucocor-
ticoids (i.e., corticosteroids) and other nontrial 
drugs were 0.2 to 3.5 percentage points (Table S2 
in the Supplementary Appendix, available at 
NEJM.org).
Primary Outcome
For each pairwise comparison of a drug and its 
control, Figure 2 and Figures S1 through S5 
show the results of unstratified Kaplan–Meier 
analyses of in-hospital mortality (with numbers 
of patients who underwent randomization, in-
hospital deaths each week and after day 28, and 
weekly denominators), along with rate ratios for 
death stratified according to age and ventilation 
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status; Figure 3 shows the stratified rate ratios ac-
cording to age and according to ventilation status. 
No trial drug had any definite effect on mortality, 
either overall (each P>0.10) or in any subgroup 
defined according to age, ventilation status at 
entry, other entry characteristics, geographic re-
gion, or glucocorticoid use (Figs. S6 through S9).
Death occurred in 301 of 2743 patients receiv-
Figure 2. Effects of Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon on In-Hospital Mortality.
Shown are Kaplan–Meier graphs of in-hospital mortality at any time (the primary outcome), comparing each treatment with its control 
without standardization for any initial patient characteristics. Insets show the same data on an expanded y axis. The rate ratios for death 
were standardized for age and for ventilation status at entry. Denominators for the few events on day 0, but not thereafter, include pa-
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ing remdesivir and in 303 of 2708 receiving its 
control (rate ratio, 0.95; 95% confidence interval 
[CI], 0.81 to 1.11; P = 0.50), in 104 of 947 patients 
receiving hydroxychloroquine and in 84 of 906 
receiving its control (rate ratio, 1.19; 95% CI, 0.89 
to 1.59; P = 0.23), in 148 of 1399 patients receiv-
ing lopinavir and in 146 of 1372 receiving its con-
trol (rate ratio, 1.00; 95% CI, 0.79 to 1.25; P = 0.97), 
and in 243 of 2050 patients receiving interferon 
and in 216 of 2050 receiving its control (rate ratio, 
Figure 3. Rate Ratios for In-Hospital Death, Subdivided by Age and Respiratory Support at Trial Entry.
Analyses in subgroups of age are stratified according to respiratory status at trial entry and vice versa, so each total is stratified for both 
factors. The percentages show Kaplan–Meier 28-day mortality. O − E denotes the observed minus expected number of deaths in patients 
assigned to active treatment. Diamonds show 95% confidence intervals for treatment effects. Squares and horizontal lines show treat-
ment effects in particular subgroups and their 99% confidence intervals, with an arrow if the upper 99% confidence limit is outside the 





















































Rate Ratio for Death
(99% CI; 95% CI for total)Control
Log-Rank Statistics for 
No. of Deaths in 
Active-Treatment Group
O – E Variance
Subgroup
no. of deaths reported/no. of patients (%)
61/961 (6.9) 59/952 (6.8)
0.0
1.08 (0.67–1.73)
  154/1282 (13.8)   161/1287 (14.2) 0.91 (0.68–1.21)
  86/500 (20.5)   83/469 (21.6) 0.93 (0.63–1.39)
203/2489 (9.4)   232/2475 (10.6) 0.86 (0.67–1.11)
  98/254 (43.0)   71/233 (37.8) 1.20 (0.80–1.80)
  301/2743 (12.5)   303/2708 (12.7) 0.95 (0.81–1.11)
P=0.50
19/335 (5.7) 19/317 (5.8) 1.10 (0.47–2.57)
  55/410 (12.1) 31/396 (7.1) 1.66 (0.95–2.91)
  30/202 (14.0)   34/193 (17.8) 0.80 (0.42–1.53)
69/862 (7.4) 57/824 (6.6) 1.16 (0.73–1.84)
35/85 (39.2) 27/82 (32.3) 1.26 (0.65–2.46)
104/947 (10.2) 84/906 (8.9) 1.19 (0.89–1.59)
P=0.23
20/511 (3.6) 27/501 (4.9) 0.77 (0.36–1.64)
66/597 (9.8) 57/596 (9.1) 1.09 (0.68–1.74)
  62/291 (20.4)   62/275 (22.7) 1.00 (0.63–1.60)
113/1287 (8.1) 111/1258 (8.7) 0.97 (0.69–1.37)
  35/112 (28.1)   35/114 (28.7) 1.08 (0.57–2.03)
148/1399 (9.7)   146/1372 (10.3) 1.00 (0.79–1.25)
P=0.97
48/720 (7.5) 35/697 (5.3) 1.44 (0.82–2.54)
122/934 (14.3) 108/973 (11.4) 1.26 (0.90–1.78)
  73/396 (19.9)   73/380 (20.9) 0.89 (0.58–1.38)
  188/1911 (10.9) 176/1920 (9.5) 1.11 (0.84–1.45)
  55/139 (42.4)   40/130 (33.8) 1.40 (0.82–2.40)
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1.16; 95% CI, 0.96 to 1.39; P = 0.11). Unstratified 
comparisons yielded similarly null findings (Fig. 2), 
as did analyses that excluded patients receiving 
glucocorticoids and multivariable sensitivity analy-
ses that estimated trial drug effects simultane-
ously (Table S3). If mechanical ventilation pre-
vented oral administration of lopinavir or other 
trial drugs, then this could have reduced any ef-
fects on mortality of assignment to those drugs, 
but prespecified analyses of mortality among 
patients not already receiving ventilation at entry 
also indicated no definite protective effect of any 
trial drug (Fig. 3).
Secondary Outcomes
The prespecified secondary outcomes were venti-
lation and time to discharge. No trial drug reduced 
the initiation of ventilation among patients not 
already receiving ventilation. Ventilation was initi-
ated after randomization in 295 patients receiving 
remdesivir and in 284 receiving its control, in 75 
patients receiving hydroxychloroquine and in 66 
receiving its control, in 126 patients receiving 
lopinavir and in 121 receiving its control, and in 
209 patients receiving interferon and in 210 receiv-
ing its control (Table S1). Figure S10 shows the 
results for the combined outcome of in-hospital 
death or ventilation initiation.
In this open-label trial, patients who would 
be considered fit for discharge might be kept in 
the hospital somewhat longer just because they 
were being given a trial drug, but information 
on time to recovery can be obtained by comparing 
the effects of different drugs on time to discharge. 
Each of the three trial treatments that were 
scheduled to last more than 7 days increased the 
percentage of patients remaining in the hospital 
at day 7 (Table 1). If one of these three drugs had 
appreciably accelerated recovery, then the sizes 
of these effects should have differed, but they did 
not. Figures S11 through S16 plot time to dis-
charge for all patients, those receiving supplemen-
tal oxygen, those not receiving supplemental oxy-
gen, those receiving ventilation, those not receiving 
ventilation, and those receiving any respiratory 
support. Each drug delayed discharge by approxi-
mately 1 to 3 days while it was being given. Di-
rectly randomized comparisons of one trial drug 
with another (Fig. S17) likewise showed no ap-
preciable differences in discharge rates while both 
drug regimens continued or after both had ended.
The supplementary analyses (Tables S2 and S3) 
tabulate co-medication (only small absolute dif-
ferences were found between each trial drug and 
its control) and provide a multivariable Cox re-
gression fitting all four treatment effects simul-
taneously (rate ratios for death were similar to 
those in Fig. 3). The analyses also (in Figs. S1 
through S9) subdivide 28-day mortality graphs 
according to ventilation status at entry and give 
subgroup analyses of rate ratios for death ac-
cording to other characteristics and according to 
glucocorticoid use (with no noteworthy sub-
group-specific or geographic variation).
All active treatment ended within 14 days, 
and the numbers of deaths during this 14-day 
period with any cardiac cause mentioned on the 
electronic death record were seven with remdesivir 
and eight with its control, four with hydroxychlo-
roquine and two with its control, six with lopi-
navir and three with its control, and six with 
interferon and eight with its control (Fig. S18). 
Many deaths from Covid-19 involve multiorgan 
failure, but no death in a patient assigned to a 
trial drug was attributed specifically by the doctor 
reporting the death to renal or hepatic disease.
Meta-Analyses
There are four trials that have compared remde-
sivir with control: the Solidarity trial (604 deaths 
in 5451 randomly assigned patients), the Adaptive 
Covid-19 Treatment Trial (ACTT-1) (136 deaths in 
1062 patients; mortality was a secondary outcome), 
and two smaller trials (41 deaths).6-9 Figure 4 
shows the mortality results from each trial, strati-
fied according to initial respiratory support. With-
in each trial, summation of the observed minus 
expected numbers of deaths with remdesivir in 
each stratum led to the stratified rate ratio for 
death in that trial. Summation of these trial-
specific observed-minus-expected subtotals then 
led to an appropriately weighted average of the 
results from all trials, which yielded a rate ratio 
for death (remdesivir vs. control) of 0.91 (95% 
CI, 0.79 to 1.05).5 Figures S19 and S20 show the 
mortality results in the trials of hydroxychloro-
quine (rate ratio, 1.09; 95% CI, 0.98 to 1.21) and 
of lopinavir (rate ratio, 1.01; 95% CI, 0.91 to 1.13).
Discussion
The main outcomes of mortality, initiation of 
ventilation, and hospitalization duration were not 
definitely reduced by any trial drug, either overall 
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or in any particular subgroup. The findings for 
mortality and for initiation of ventilation cannot 
have been appreciably biased by the open-label 
design without placebos, or by variation in local 
care or patient characteristics, and were little 
affected when homogeneity was increased by 
stratification according to geographic region, age, 
or use of ventilation at entry. No trial drug reduced 
the initiation of mechanical ventilation. The simi-
larity of this null effect for all four drugs is 
further evidence that none has any material ef-
fect on major disease progression, a conclusion 
supported by analyses of the combined outcome 
of death or ventilation initiation.
Although assignment to any of the active trial 
treatments in this open-label trial somewhat 
delayed discharge from the hospital, this could 
have been because some recovered patients oth-
erwise fit for discharge were kept in the hospital 
merely to continue their trial treatment. In all 
patients and in those not receiving ventilation, 
assignment to each active trial drug increased 
Figure 4. Meta-Analysis of Mortality in Trials of Random Assignment of Remdesivir or Its Control to Hospitalized Patients with Covid-19.
Percentages show Kaplan–Meier 28-day mortality. Values for observed minus expected number of deaths (O − E) are log-rank O − E for 
the Solidarity trial, O − E from 2-by-2 tables for the Wuhan7 and international8 trials, and w.loge hazard ratio for each stratum in the Adap-
tive Covid-19 Treatment Trial (ACTT-1)6 (with the weight w being the inverse of the variance of the loge hazard ratio, which was calculated 
from the confidence interval of the hazard ratio). Rate ratios were calculated by taking the loge rate ratio to be (O − E)/V with a Normal 
distribution and variance 1/V. Subtotals or totals of (O − E) and of V yield inverse-variance–weighted averages of the loge rate ratios. For 
balance, controls in the 2:1 trials were counted twice in the control totals and subtotals. Diamonds show 95% confidence intervals for 
treatment effects. Squares and horizontal lines show treatment effects in particular subgroups and their 99% confidence intervals, with 
an arrow if the upper 99% confidence limit is outside the range shown. The area of each square is proportional to the variance of O − E 
in the subgroup it describes.
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Rate Ratio for Death
(99% CI; 95% CI for totals)
Observed–Expected
No. of Deaths in 
Remdesivir GroupControlSubgroup
no. of deaths reported/no. of patients (%)
Value Variance
11/661 (2.0) 13/664 (2.1)
0.0
0.90 (0.31–2.58)
  192/1828 (12.2)   219/1811 (13.8) 0.85 (0.66–1.09)
  98/254 (43.0)   71/233 (37.8) 1.20 (0.80–1.80)
  301/2743 (12.5)    303/2708 (12.7) 0.94 (0.80–1.10)
3/75 (4.1) 3/63 (4.8) 0.82 (0.10–6.61)
  9/232 (4.0)   25/203 (12.7) 0.30 (0.11–0.81)
19/95 (21.2) 20/98 (20.4) 1.02 (0.44–2.34)
  28/131 (21.9)   29/154 (19.3) 1.13 (0.57–2.23)
  59/533 (11.1)   77/518 (14.9) 0.82 (0.58–1.16)
11/129 (8.5)         (7/68)×2 (10.3) 0.81 (0.21–3.07)
11/29 (37.9)         (3/10)×2 (30.0) 1.40 (0.20–9.52)
5/384 (1.3)         (4/200)×2 (2.0) 0.64 (0.10–3.94)
27/542 (5.0)       (14/278)×2 (5.0) 0.86 (0.42–1.77)
231/3309 (7.0) 282/3277 (8.6) 0.80 (0.63–1.01)
156/509 (30.6) 126/505 (25.0) 1.16 (0.85–1.60)
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the time to discharge by approximately 1 to 3 days 
while treatment continued. Because no treatment 
had much effect on death or progression to ven-
tilation, the similarity of these four moderate 
delays of discharge suggests that none of the 
four treatments had a pharmacologic effect that 
substantially reduced time to recovery (i.e., fit-
ness for discharge). In particular, it suggests at 
most only a small effect of remdesivir on time to 
recovery, a conclusion supported by the directly 
randomized comparisons between remdesivir and 
the other three trial drugs.
ACTT-1, which examined remdesivir, was pla-
cebo-controlled,6 which avoids any bias in time to 
discharge. In that trial, however, the proportion 
of lower-risk patients (i.e., those not already re-
ceiving high-flow oxygen or ventilation) happened 
to be appreciably greater in the remdesivir group 
than in the placebo group. This chance imbal-
ance might account for some of the differences 
in time to recovery between ACTT-1 and the Soli-
darity trial.
The chief aim of the Solidarity trial was to 
help determine whether any of four repurposed 
antivirals could at least moderately affect in-
hospital mortality. Its results should be consid-
ered in the context of the evidence on mortality 
from all trials, but for remdesivir and for inter-
feron it provides more than three fourths of that 
evidence (Fig. 4). Stratification of the findings 
according to initial respiratory support again 
facilitates allowance for the remdesivir group in 
ACTT-1 having, by chance, started with a greater 
proportion of low-risk patients and a smaller 
proportion of high-risk patients than the placebo 
group. The stratified rate ratios for death in the 
Solidarity trial and ACTT-1 are compatible with 
each other, and either singly or together they are 
compatible with there being little or no effect of 
remdesivir on mortality.
With an appropriately weighted average of the 
stratified results from each of the four trials,5 
the rate ratio for death with remdesivir as com-
pared with control was 0.91 (95% CI, 0.79 to 1.05). 
Interpretation of this should chiefly reflect not 
the P value (P = 0.20) or point estimate (rate ratio, 
0.91) but the confidence interval (0.79 to 1.05), 
which shows the range of rate ratios for death 
that are compatible with the weighted average of 
the findings from all trials. This does not sup-
port the suggestion that remdesivir can prevent 
a substantial fraction of all deaths. The confi-
dence interval is compatible with prevention of a 
small fraction of all deaths, but it is also com-
patible with prevention of no deaths.
Statistical uncertainties are magnified if at-
tention is restricted to particular subgroups or 
time periods.10 If remdesivir has no effect on 
mortality, then chance could well produce some-
what favorable findings in a subgroup of the 
results for all trials or striking findings in a 
selected subgroup of a particular trial (as in the 
unplanned subgroup of ACTT-1 in which the rate 
ratio for death was 0.30) (Fig. 4). Although both 
the Solidarity trial and ACTT-1 envisaged sepa-
rate analyses involving lower-risk and higher-
risk patients, they did not define how this sub-
division would apply to mortality analyses. The 
ACTT-1 protocol prespecified separate analyses 
of time to recovery among those with mild-to-
moderate disease not receiving supplemental 
oxygen, as did the recent Food and Drug Admin-
istration reanalyses,11 which categorized anyone 
receiving even low-flow supplemental oxygen as 
having severe disease. This subdivision, however, 
leaves few deaths in the no-supplemental-oxygen 
category (death in 3 of 75 patients with remde-
sivir and in 3 of 63 with placebo in ACTT-1, in 
11 of 661 patients with remdesivir and in 13 of 
664 with its control in the Solidarity trial, and in 
5 of 384 patients with remdesivir and in 4 of 200 
with the standard of care in an international 
trial with a 2:1 randomization ratio8).
To augment these small numbers of deaths, 
the subtotals in Figure 4 include low-flow oxy-
gen with no supplemental oxygen, which yields 
a large lower-risk subgroup and a small higher-
risk subgroup. With this nonprespecified sub-
grouping, there appears to be an absolute reduc-
tion of approximately 1 to 2 percentage points in 
mortality among lower-risk inpatients and an 
absolute increase of approximately 5 to 6 percent-
age points among higher-risk inpatients. These 
absolute differences in the meta-analysis of all 
four trials are similar to the absolute differences 
seen when the Solidarity trial is subdivided ac-
cording to ventilation status at entry. Neither 
subgroup should, however, be considered in isola-
tion from the other or from the confidence in-
terval for overall mortality.
For hydroxychloroquine and lopinavir, the 
Solidarity trial showed no definite effect on mor-
tality in any subgroup. The only other substantial 
trial is the Randomized Evaluation of Covid-19 
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Therapy (RECOVERY) trial,12,13 which for these 
two drugs was larger than the Solidarity trial and 
also showed no benefit. Combination of both trials 
reinforces these null findings (Figs. S19 and S20).
For hydroxychloroquine, the joint rate ratio for 
death (combining the Solidarity and RECOVERY 
trials) was 1.10 (95% CI, 0.98 to 1.23), with no 
apparent benefit whether the patient was receiv-
ing ventilation or not. This confidence interval 
rules out any material benefit from this hydroxy-
chloroquine regimen in hospitalized patients with 
Covid-19. It is compatible with some adverse ef-
fect but is not good evidence for any adverse effect 
and is not a safety signal. Despite concerns that 
the loading dose could be temporarily cardio-
toxic,4 in neither trial was there any excess mor-
tality during the first few days, and cardiac deaths 
were too few to be reliably informative. A recent 
meta-analysis identified 15 small, randomized 
trials with nonzero mortality14; combining all 17 
hydroxychloroquine trials yields a rate ratio of 
1.09 (95% CI, 0.98 to 1.21), which still rules out 
any material benefit.
For lopinavir, which was always administered 
with ritonavir, the joint rate ratio for death 
(combining the Solidarity and RECOVERY trials 
and the only informative smaller trial15) was 1.01 
(95% CI, 0.91 to 1.13). Although lopinavir tablets 
could not be swallowed by patients receiving ven-
tilation, there was no apparent benefit in analyses 
that involved only those not already receiving 
ventilation at entry. This confidence interval sug-
gests no material effect on mortality and rules 
out a 10% proportional reduction. An add-on 
study within the Solidarity trial, Discovery, re-
corded many clinical variables and identified an 
unexpected increase in the creatinine level (per-
haps because blood lopinavir levels are higher 
than in patients with human immunodeficiency 
virus infection receiving similar doses16,17), but 
the Solidarity and RECOVERY trials recorded no 
specifically renal or hepatic deaths with lopinavir.
For interferon beta-1a, no other large trials 
exist. With 4000 patients, the rate ratio for death 
in the Solidarity trial was 1.16 (95% CI, 0.96 to 
1.39), or 1.12 (95% CI, 0.83 to 1.51) without 
lopinavir co-administration; these findings sug-
gest no mortality reduction. Subcutaneous and 
intravenous interferon have different pharmaco-
kinetic characteristics,18,19 and glucocorticoids 
could affect interferon signaling,20,21 but the 
clinical relevance of both issues is unclear. Most 
interferon was administered subcutaneously, be-
cause intravenous interferon was used only in 
patients receiving high-flow oxygen or ventilation, 
and distribution of it began only in late May, just 
before strong evidence emerged of glucocorticoid 
efficacy in such patients.22,23 Hence, few patients 
received intravenous interferon without a gluco-
corticoid. Approximately half the patients who 
were assigned to interferon (and half their con-
trols) received glucocorticoids, but the rate ratio 
for death with interferon as compared with its 
control seemed unaffected by glucocorticoid use. 
Randomization to interferon was discontinued 
on October 16, but other trials continue. A re-
port that nebulized interferon beta-1a might be 
effective involved only approximately 100 pa-
tients with Covid-19 (ClinicalTrials.gov number, 
NCT04385095), but the ongoing placebo-con-
trolled ACTT-3 of subcutaneous interferon beta-
1a aims to involve 1000 patients (NCT04492475), 
with examination of time to recovery.
For each of these four repurposed nonspecific 
antivirals, several thousand patients have now 
undergone randomization in various trials. The 
unpromising overall findings from the regimens 
tested suffice to refute early hopes, based on 
smaller or nonrandomized studies, that any of 
these regimens will substantially reduce inpatient 
mortality, the initiation of mechanical ventilation, 
or hospitalization duration. Narrower confidence 
intervals would be helpful (particularly for rem-
desivir), but the main need is for better treat-
ments. The Solidarity trial has been recruiting 
approximately 2000 patients per month, and ef-
ficient factorial designs may allow it to assess 
further treatments, such as immune modulators 
or anti–SARS-Cov-2 monoclonal antibodies.
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